| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000737 | Dna catabolic process, endonucleolytic | Increases phenotype | PMID:34352653; PMID:36916050 |
| GO:0001675 | Acrosome assembly | Increases phenotype | PMID:32294523 |
| GO:0004035 | Alkaline phosphatase activity | Increases phenotype | PMID:35850439 |
| GO:0004069 | L-aspartate:2-oxoglutarate aminotransferase activity | Increases phenotype | PMID:32651782; PMID:35850439 |
| GO:0004197 | Cysteine-type endopeptidase activity | Decreases phenotype | PMID:38040083 |
| GO:0004364 | Glutathione transferase activity | Affects phenotype | PMID:25721553; PMID:36916050 |
| GO:0004457 | Lactate dehydrogenase activity | Increases phenotype | PMID:35850439 |
| GO:0004602 | Glutathione peroxidase activity | Increases phenotype | PMID:36916050 |
| GO:0004784 | Superoxide dismutase activity | Affects phenotype | PMID:25721553; PMID:32651782; PMID:36916050 |
| GO:0006006 | Glucose metabolic process | Affects phenotype | PMID:38050659 |
| GO:0006116 | Nadh oxidation | Decreases phenotype | PMID:25943759 |
| GO:0006600 | Creatine metabolic process | Affects phenotype | PMID:32651782 |
| GO:0006641 | Triglyceride metabolic process | Affects phenotype | PMID:32810590; PMID:38050659 |
| GO:0006749 | Glutathione metabolic process | Increases phenotype | PMID:30777931; PMID:32651782 |
| GO:0006754 | Atp biosynthetic process | Affects phenotype | PMID:32294523 |
| GO:0006809 | Nitric oxide biosynthetic process | Increases phenotype | PMID:27067106 |
| GO:0006974 | Cellular response to dna damage stimulus | Increases phenotype | PMID:19591892; PMID:32651782 |
| GO:0008219 | Cell death | Increases phenotype | PMID:27067106; PMID:30130558 |
| GO:0008284 | Positive regulation of cell population proliferation | Affects phenotype | PMID:27816694; PMID:28531659 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:29149346 |
| GO:0009566 | Fertilization | Decreases phenotype | PMID:32294523 |
| GO:0009790 | Embryo development | Decreases phenotype | PMID:30130558; PMID:32294523 |
| GO:0010917 | Negative regulation of mitochondrial membrane potential | Increases phenotype | PMID:38040083 |
| GO:0016042 | Lipid catabolic process | Increases phenotype | PMID:25721553; PMID:27067106; PMID:32651782 |
| GO:0016209 | Antioxidant activity | Decreases phenotype | PMID:36113622 |
| GO:0018108 | Peptidyl-tyrosine phosphorylation | Decreases phenotype | PMID:32294523 |
| GO:0018158 | Protein oxidation | Increases phenotype | PMID:34352653; PMID:36916050 |
| GO:0019432 | Triglyceride biosynthetic process | Increases phenotype | PMID:27103584; PMID:30738135; PMID:31199990 |
| GO:0019479 | L-alanine oxidation to d-lactate and ammonia | Increases phenotype | PMID:25943759 |
| GO:0019627 | Urea metabolic process | Affects phenotype | PMID:32651782 |
| GO:0030263 | Apoptotic chromosome condensation | Increases phenotype | PMID:30777931; PMID:34352653 |
| GO:0031323 | Regulation of cellular metabolic process | Affects phenotype | PMID:28965233 |
| GO:0031959 | Mineralocorticoid receptor signaling pathway | Increases phenotype | PMID:29149346 |
| GO:0032125 | Micronucleus organization | Affects phenotype | PMID:36113622 |
| GO:0034440 | Lipid oxidation | Increases phenotype | PMID:30777931; PMID:30777931; PMID:36916050; PMID:34352653; PMID:36916050 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:35850439 |
| GO:0045333 | Cellular respiration | Decreases phenotype | PMID:34044035 |
| GO:0045444 | Fat cell differentiation | Increases phenotype | PMID:27103584 |
| GO:0045666 | Positive regulation of neuron differentiation | Decreases phenotype | PMID:27816694 |
| GO:0045687 | Positive regulation of glial cell differentiation | Increases phenotype | PMID:27816694 |
| GO:0045819 | Positive regulation of glycogen catabolic process | Increases phenotype | PMID:25943759 |
| GO:0045821 | Positive regulation of glycolytic process | Increases phenotype | PMID:25943759 |
| GO:0046449 | Creatinine metabolic process | Affects phenotype | PMID:32651782 |
| GO:0048240 | Sperm capacitation | Decreases phenotype | PMID:32294523 |
| GO:0048589 | Developmental growth | Increases phenotype | PMID:31708466 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Affects phenotype | PMID:34044035 |
| GO:0051882 | Mitochondrial depolarization | Increases phenotype | PMID:35850439 |
| GO:0140042 | Lipid droplet formation | Increases phenotype | PMID:38050659 |
| GO:1901216 | Positive regulation of neuron death | Increases phenotype | PMID:30777931 |
| GO:1901670 | Negative regulation of superoxide dismutase activity | Increases phenotype | PMID:30777931 |
| GO:1903787 | Negative regulation of glutathione biosynthetic process | Increases phenotype | PMID:36113622 |
| GO:2000376 | Positive regulation of oxygen metabolic process | Decreases phenotype | PMID:25943759 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.